Speeding up new vaccine development
Manufacturing on the Go (MANGO) automates the manufacture of virus-like particles used in vaccine development.
This ground-breaking, interdisciplinary health tech research is co-led by a team from Leeds and foundations, organisations and institutions in Canada and Brazil. Together, they have developed a device which could help reduce new vaccine production time to less than 100 days.
The UK’s Centre for Process Innovation (CPI), a non-profit tech company that helps businesses and researchers develop new products, has been awarded £2.16m to test the device in a proof-of-concept study.
Using new technology in vaccine production could help us to create vaccines significantly faster, cut costs and improve access to immunisation globally.
— Professor Nicola Stonehouse
Read the research newsImpact
- Global partnerships: collaborative research between institutions and organisations across the world
- Improving health inequalities: the team are committed to enabling global equitable access to vaccines
- Health impact: quicker vaccination processes could help to cut medical costs and improve access to immunisation globally.
Key Information
- Major funders: Coalition for Epidemic Preparedness Innovations (CEPI), Centre for Process Innovation (CPI)
- Partners and collaborators: Imperial College London, the University of Toronto, Liberum Biotech, the University of Waterloo, Oswaldo Cruz Foundation (FioCruz)
- Disciplines: molecular and cellular biology, biological sciences, medicine
- Investigators: Professor Nicola Stonehouse.
Keywords: vaccine development, disease prevention, vaccination, medicine and health, healthcare, NHS, immunity, cell-free expression, pandemic, COVID-19, coronavirus